“`html
The U.S. health care sector is projected to lead market performance in 2026, driven by growth in large-cap pharmaceuticals, according to Zacks Investment Research. Key data indicate that the Zacks Large Cap Pharmaceuticals industry is ranked in the top 37% out of approximately 250 industry groups, suggesting a strong potential for outperformance over the next 3 to 6 months.
Notably, Eli Lilly (LLY) has recently reached an all-time high, boosted by a significant drug pricing deal with Medicare for its weight loss drug, Zepbound, and a series of partnerships focused on AI-driven drug discovery. Analysts forecast earnings per share for Eli Lilly to grow by 40.9% in 2026, with revenue expected to rise by 23.3% to $78.84 billion.
Overall, the combination of resilient demand, technological innovation, and favorable policies positions health care as a promising investment sector in an unpredictable market.
“`
